Fluvoxamine

⇄

cytochrome P450 family 1 subfamily A member 2 ; Homo sapiens







106 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
51 11955666 In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. 2002 May 1
52 12038880 Clinically significant drug interactions with antidepressants in the elderly. 2002 1
53 12352274 Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. 2002 Oct 1
54 12452751 Fluvoxamine interaction with warfarin. 2002 Dec 1
55 12523495 Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. 2002 Jul-Aug 2
56 11240973 Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. 2001 Mar 1
57 11317475 Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. 2001 Mar 1
58 11477325 Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. 2001 Aug 1
59 11519155 [Pharmacokinetics and drug interactions of antidepressive agents]. 2001 Aug 1
60 11599655 Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. 2001 Aug 1
61 11704898 [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. 2001 Nov 1
62 11719727 Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. 2001 Nov 4
63 11791889 Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. 2001 1
64 11791895 The major fluvoxamine metabolite in urine is formed by CYP2D6. 2001 Nov 3
65 24921690 Caffeine: The forgotten variable. 2001 1
66 10653206 Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. 2000 Feb 1
67 10674711 Pharmacokinetics of selective serotonin reuptake inhibitors. 2000 Jan 1
68 10774624 Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? 2000 Apr 1
69 10877005 Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. 2000 May 2
70 10982203 Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. 2000 Aug 1
71 11085201 Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. 2000 Oct 1
72 11249525 Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. 2000 Mar 1
73 10192755 Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. 1999 Feb 2
74 10456487 Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. 1999 Jul 1
75 10471171 Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. 1999 May 1
76 10550852 Elevated plasma levels of clozapine after concomitant use of fluvoxamine. 1999 Oct 1
77 10587283 Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. 1999 Dec 1
78 9617978 Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. 1998 Jun 7
79 9757149 Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. 1998 Sep 6
80 9817620 Differences in interactions of SSRIs. 1998 Sep 2
81 9868741 Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. 1998 Dec 3
82 9923577 Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. 1998 Nov-Dec 1
83 10022747 Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. 1998 Apr 3
84 9029748 Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. 1997 Feb 1
85 9105404 Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. 1997 Feb 21 2
86 9209244 Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. 1997 Jun 1
87 9435993 Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. 1997 Dec 1
88 9442550 Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. 1997 Nov 1
89 10950475 Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. 1997 Apr 1
90 8610817 Newer antidepressants and the cytochrome P450 system. 1996 Mar 1
91 8732441 Are pharmacokinetic drug interactions with the SSRIs an issue? 1996 Mar 2
92 8823236 Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. 1996 Aug 4
93 8880055 Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. 1996 3
94 8968657 Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. 1996 Dec 1
95 9032002 Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. 1996 Dec 1
96 7586931 Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. 1995 Oct 3
97 7617560 Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. 1995 Apr 1
98 7622807 Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. 1995 Mar 1
99 7742153 Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. 1995 Feb 3
100 8567194 Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. 1995 1